Medical Editor: John P. Cunha, DO, FACOEP
ChiRhoStim (Human Secretin) Injection is a gastrointestinal peptide hormone used for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction; stimulation of gastrin secretion to aid in the diagnosis of gastrinoma; and facilitation of the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). Common side effects of ChiRhoStim include:L
- nausea or vomiting
- abdominal pain
- increased heart rate
- stomach upset
- warm or burning feeling in stomach or abdomen
- clammy skin
- low blood pressure
- drowsiness, and
- tingling in legs
The dose of ChiRhoStim for stimulation of pancreatic secretions is 0.2 mcg/kg body weight by intravenous injection over 1 minute. ChiRhoStim may interact with anticholinergic drugs. Tell your doctor all medications and supplements you use. During pregnancy, ChiRhoStim should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding. /p>
Our ChiRhoStim (Human Secretin) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Clinical Trials Experience
Because clinical trials are conducted under varying conditions, adverse reaction rates observed during the clinical trials of a drug cannot always be directly compared to the rates observed during the clinical trials of another drug and may not reflect the adverse reaction rates observed in practice.
The data described below reflect exposure to ChiRhoStim® in 531 patients from an open-label clinical trial. The population consisted of patients aged 1 to 91 years, 185 males, 346 females, 480 Caucasians, 31 Blacks, 12 American Indians, 6 Hispanics, and 2 Asians with known or suspected diseases of the exocrine pancreas including chronic pancreatitis and pancreatic cancer. Most patients received a single dose of ChiRhoStim® in a dose range of 0.2 mcg/kg to 0.4 mcg/kg. The most common adverse reactions (reported in at least 2 patients in the trial) are listed in Table 2.
TABLE 2 :Adverse Reactions in at Least 2 Patients
Treated with a Single-Dose of ChiRhoStim® in a Clinical Trial
|Adverse Reaction||ChiRhoStim® Number of Patients
N = 531
Read the entire FDA prescribing information for ChiRhoStim (Human Secretin)